



Please find our Research on Bloomberg BRYG <GO>)

18th October 2016


	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	18086.4	-0.29%	+3.80%
S&P 500	2126.5	-0.30%	+4.04%
Nasdaq	5199.82	-0.28%	+3.84%
Nikkei	16963.61	+0.38%	-11.21%
Stoxx 600	337.425	-0.74%	-7.76%
CAC 40	4450.23	-0.46%	-4.03%
Oil /Gold			
Crude WTI	50.35	0.00	+35.35%
Gold (once)	1256.66	+0.26%	+18.29%
Currencies/Rates			
EUR/USD	1.0992	-0.10%	+1.19%
EUR/CHF	1.08835	+0.06%	+0.09%
German 10 years	-0.015	-15.56%	-102.40%
French 10 years	0.286	+3.17%	-70.88%
Euribor	-	+-%	+-%
Upcoming BG events :			
Date			

Date	
21st-Oct	KORIAN (BG Geneva roadshow with CFO)
28th-Oct	IMERYS (Paris roadshow)
8th-Nov	LVMH (BG Luxembourg roadshow with IR)
14th-Nov/ 15th-Nov	4th Paris Healthcare Conference
18th-Nov	ENGIE (BG Luxembourg roadshow with IR)
24th-Nov	IMERYS (BG London roadshow with IR)

Recent reports :

Date	
13th-Oct	TEMENOS Success breeds success
12th-Oct	BOUYGUES Do not forget construction!
11th-Oct	A INBEV Fox in the Hen House
7th-Oct	SAINT GOBAIN : Endless sluggishness is not our scenario (report released today)
7th-Oct	ALTICE Lower risk profile
7th-Oct	ALTICE Lower risk profile

List of our Reco & Fair Value : Please click here to download



BG's Wake Up Call

ALTRAN TECHNOLOGIES

BUY, Fair Value EUR15 (+12%)

NEUTRAL, Fair Value EUR65 (+2%)

Acquisition of Benteler Engineering Services in Germany

This morning Altran announced the acquisition of Benteler Engineering Services, for an undisclosed sum. We estimate this acquisition, which is in line with the "Altran 2020 Ignition" plan, will allow the company to increase its size in Germany by 30%, covering the entire product development process in Automotive. We view this deal as positive for Altran, although investors needs to get some colour about the profitability of this business.

DANONE

Deteriorating sales trend

Q3 2016 sales decreased 1.8% to EUR5537m (consensus: EUR5.55bn and our estimate: EUR5.48bn). Organic sales growth stood at 2.1% (consensus: +2.4% and our estimate: +1.4%), implying a strong deterioration vs Q1 (+3.5%) and Q2 (+4.1%), which was driven by all divisions excluding Medical Nutrition. Volumes dropped 0.7% (consensus: +0.2% and our estimate: -0.6%) while price/mix rose 2.8% (consensus: +2.2% and our estimate: +2%).

RÉMY COINTREAU

BUY-Top Picks, Fair Value EUR84 (+12%)

Sharp acceleration in sales trend

Q2 2016/17 sales increased 6.2% to EUR294.8m, 4% above expectations (consensus: EUR284m and our estimate: EUR283m). The group posted 7.4% organic sales growth (consensus: +4.3% and our estimate: +3.3%), implying a strong improvement vs Q1 (flat sales), driven by Cognac and Liqueurs & Spirits. These two divisions were impacted in the previous quarter by some destocking following a global hike in prices at the beginning of 2016/17

In brief...

BURBERRY, Underlying sales down 4% in H1! Q2 retail sales rebound thanks to GBP weakness BUREAU VERITAS, Q3 revenue: Substantially lower and FY guidance downgraded

BG Building Materials CHART #12

Imerys: Baker Hughes North America rig count

TMT

Altran Technologies Price EUR13.36 Bloomberg Reuters 12-month High / Low (EUR) Market Cap (EURm) Ev (BG Estimates) (EURm) Avg. 6m daily volume (000) 3y EPS CAGR 1 M 3 M 6 M Absolute perf. -0.3% 8.9% 9.5% Softw.& Comp. 9.1% -1.1% 9.0%

01.40	1.170	7.070	7.170	1.070
DJ Stoxx 600	-0.1%	-0.1%	-1.6%	-7.8%
YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	1,945	2,125	2,307	2,468
% change		9.3%	8.6%	7.0%
EBITDA	208	237	273	316
EBIT	155.0	187.0	227.0	266.0
% change		20.6%	21.4%	17.2%
Net income	123.0	140.0	164.0	192.0
% change		13.8%	17.1%	17.1%
	2015	2016e	2017e	2018e
Operating margin	9.6	10.1	10.8	11.6
Net margin	5.2	5.7	6.4	7.1
ROE	12.6	13.9	15.3	16.1
ROCE	15.0	15.2	16.8	19.5
Gearing	18.0	19.0	8.0	-4.0
(€)	2015	2016e	2017e	2018e
EPS	0.70	0.80	0.93	1.09
% change	-	14.3%	16.3%	17.2%
P/E	19.1x	16.7x	14.4x	12.3x
FCF yield (%)	3.4%	4.7%	6.1%	7.0%
Dividends (€)	0.19	0.23	0.28	0.33
Div yield (%)	1.4%	1.7%	2.1%	2.5%
EV/Sales	1.3x	1.2x	1.1x	0.9x
EV/EBITDA	12.0x	10.6x	8.9x	7.3x
EV/EBIT	13.4x	11.7x	9.8x	8.0x

Return to front page

BUY

Acquisition of Benteler Engineering Services in Germany

Fair Value EUR15 (+12%)

This morning Altran announced the acquisition of Benteler Engineering Services, for an undisclosed sum. We estimate this acquisition, which is in line with the "Altran 2020 Ignition" plan, will allow the company to increase its size in Germany by 30%, covering the entire product development process in Automotive. We view this deal as positive for Altran, although investors needs to get some colour about the profitability of this business.

ANALYSIS

ALT FP

ALTR PA

13.7 / 9.9

2 3 4 9

2,511

209.8

15 9%

8.3%

4.8%

31/12/15

- What is Benteler Engineering Services? Founded in 2001 as the engineering department of Benteler Automotive through the acquisition of the Product Development & Engineering department of the Dutch company NedCar, and now headquartered in Munich, Benteler Engineering Services, a specialist in design and engineering services for the automotive industry. The business, currently held by by the Benteler Group serves large OEMs and tier-1 suppliers such as BMW, Volkswagen, Volvo, Ford, Porsche and Daimler. It employs 700 staff out of 30,000 staff for the Benteler Group -, essentially in Germany, but also in The Netherlands and in Sweden. Revenues are not disclosed, but we estimate them, based on a rule of thumb of EUR0.09-0.1m per employee, at c. EUR65-70m or 2% of Altran's total revenues.
- **Rationale of the deal**. This acquisition is in line with Altran's "2020 Ignition" plan, for which it expected to acquire EUR500m revenues through acquisitions, including in Germany as a strategic country. We estimate that in 2017 Germany will generate c. EUR300m sales or 12% of total revenues (vs. 10% previously), or a size increase of nearly 30%. While the Automotive R&D market in Germany is undergoing a significant transformation and consolidation due to the amendment of the AÜG labour legislation which leads carmakers and suppliers to move away from staffing services and develop project-based services -, Altran with Benteler Engineering Services provides services across the entire product development process (project management, quality management, product data management, etc.) with real engineering capabilities and prototyping facilities in electrical & electric, electrification, exterior & interior body, and chassis.
- **Still early to determine the impact to our EPS forecasts.** While we estimate the positive impact to revenues at c. 2%, we have no idea of the margins Benteler Engineering Services generates. As such, we do not update our model and we expect the management will give more details of this deal for Q3 2016 sales on 27th October. At first glance we would say this kind of acquisitions may be done for less than 1x revenues, but it is too early to be sure of it.

VALUATION

- Altran's shares are trading at est. 11.7x 2016 and 9.8x 2017 EV/EBIT multiples.
- Net debt on 30th June 2016 was EUR217.2m (net gearing: 27%).



NEXT CATALYSTS

Q3 2016 sales on 27th October before markets open.

Click here to download



Analyst : Gregory Ramirez 33(0) 1 56 68 75 91 gramirez@bryangarnier.com Sector Team : Richard-Maxime Beaudoux Thomas Coudry Dorian Terral

Food & Beverages

Danone Price EUR63.81 Fair Value EUR65 (+2%) BN FP Bloomberg Reuters DANO PA 12-month High / Low (EUR) 70.3 / 58.1 Market Cap (EUR) 41.852 Ev (BG Estimates) (EUR) 60,166 Avg. 6m daily volume (000) 1 556 3y EPS CAGR 6.5% **ANALYSIS** 1 M 6 M 31/12/15 3 M Absolute perf. -0.2% -2.9% 2.7% 2.5% Food & Bev. -0.9% -3.0% -0.2% -2.5% DJ Stoxx 600 -0.1% -0.1% -1.6% -7.8% YEnd Dec. (EURm) 2015 2016e 2017e 2018e Sales 22,412 21,899 25,880 27,252 -2.3% 18 2% 5.3% % change EBIT 2.892 2.980 3,493 3.775 % change 3.0% 17.2% 8.1% 1,791 1,871 1,966 2,180 Net income . % change 4 5% 51% 10 9% 2016e 2015 2017e 2018e 13.9 129 13.6 13.5 Operating margin 8.0 8.5 7.6 8.0 Net margin ROF 10.2 147 15.3 15.7 ROCE 11.0 124 14.0 148 Gearing 61.6 141.3 127.2 113.1

(EUR)	2015	2016e	2017e	2018e
EPS	2.93	3.04	3.19	3.54
% change	-	3.6%	5.1%	10.9%
P/E	21.8x	21.0x	20.0x	18.0x
FCF yield (%)	3.9%	4.3%	4.4%	4.7%
Dividends (EUR)	1.60	1.66	1.74	1.93
Div yield (%)	2.5%	2.6%	2.7%	3.0%
EV/Sales	2.2x	2.7x	2.3x	2.2x
EV/EBIT	17.2x	20.2x	17.0x	15.5x

Deteriorating sales trend

Q3 2016 sales decreased 1.8% to EUR5537m (consensus: EUR5.55bn and our estimate: EUR5.48bn). Organic sales growth stood at 2.1% (consensus: +2.4% and our estimate: +1.4%), implying a strong deterioration vs Q1 (+3.5%) and Q2 (+4.1%), which was driven by all divisions excluding Medical Nutrition. Volumes dropped 0.7% (consensus: +0.2% and our estimate: -0.6%) while price/mix rose 2.8% (consensus: +2.2% and our estimate: +2%).

- Q3 2016 sales decreased 1.8% to EUR5537m (consensus: EUR5.55bn and our estimate: EUR5.48bn). Organic sales growth stood at 2.1% (consensus: +2.4% and our estimate: +1.4%), implying a strong deterioration vs Q1 (+3.5%) and Q2 (+4.1%), which was driven by all divisions excluding Medical Nutrition. Volumes dropped 0.7% (consensus: +0.2% and our estimate: -0.6%) while price/mix rose 2.8% (consensus: +2.2% and our estimate: +2%). By division:
 - Fresh Dairy Products (49% of sales): Q3 organic sales were up 2.2% (consensus: +2.5% and our estimate: +1.5%) with volumes down 2.3% and price/mix up 4.5%. This represented a slowdown vs H1 (+2.3% in Q1 and +3% in Q2), reflecting the tough macroeconomic backdrop in LATAM and Russia and intense price competition in the US (because of weak milk prices).
- Early Life Nutrition (21% of group's sales): The division posted 1.7% organic sales growth in Q3 (consensus: +2.5% and our estimate: +1%), implying a strong deterioration vs the first half of the year (+4.8% in Q1 and +7.2% in Q2). Traders in the cross border C2C channel are currently destocking due to tougher regulations.
- Waters (22% of group's sales): Organic sales were down 0.1% in Q3 (consensus: +1% and our estimate: 0%), mainly due to destocking of Mizone. The non-alcoholic beverages market has slowed significantly in China and is now showing flat to up low-single-digit. Six months ago, it was running at 5-10%. Flooding in China also penalised the division's performance.
- Medical Nutrition (7% of group's sales): Organic sales increased 9.7% over the quarter (consensus and our estimate: +7%). Emerging countries, especially China and Brazil, continued to drive growth.

Danone has confirmed its annual guidance for 1/ organic sales growth of between 3% and 5% and 2/ an improvement in EBIT margin of 50-60bps in organic. We currently expect organic sales and EBIT margin to rise 3% and 50bps in 2016. The group should provide more details on its outlook in the conference call scheduled for 9 am CET. The press release indicates that the destocking of Mizone and baby food products sold in the indirect channel should continue.

VALUATION

Our DCF points to a Fair Value of EUR65. At yesterday's share price, the stock is trading at 21.0x P/E 2016e and 20.0x P/E 2017e, globally in line with the peer average.

NEXT CATALYSTS

Nestlé will release its Q3 sales on 20th October.

Click here to download



Analyst : Virginie Roumage 33(0) 1.56.68.75.22 vroumage@bryangarnier.com

Sector Team : Nikolaas Faes Loïc Morvan Antoine Parison Cédric Rossi

Return to front page

NEUTRAL

Food & Beverages Rémy Cointreau

Price EUR75.01

Bloomberg Reuters 12-month High / Low (EUR) Market Cap (EUR) Ev (BG Estimates) (EUR) Avg. 6m daily volume (000) 3y EPS CAGR			RCO FP RCOP.PA 80.4 / 58.1 3,727 4,181 90.60 13.8%		
	1 M	3 M	6 M 3	1/12/15	
Absolute perf.	2.0%	-3.1%	9.4%	13.6%	
Food & Bev.	-0.9%	-3.0%	-0.2%	-2.5%	
DJ Stoxx 600	-0.1%	-0.1%	-1.6%	-7.8%	
YEnd Mar. (EURm)	03/16	03/17e	03/18e	03/19e	
Sales	1,051	1,076	1,140	1,232	
% change		2.4%	6.0%	8.1%	
EBITDA	200	227	252	284	
EBIT	178.4	206.6	229.4	258.4	
% change		15.8%	11.0%	12.6%	
Net income	110.4	127.9	150.4	171.2	
% change		15.9%	17.6%	13.8%	
	03/16	03/17e	03/18e	03/19e	
Operating margin	17.0	19.2	20.1	21.0	
Net margin	10.5	11.9	13.2	13.9	
ROE	9.9	12.0	14.4	16.0	
ROCE	16.5	17.3	18.0	18.3	
Gearing	41.2	42.4	40.2	34.0	
(EUR)	03/16	03/17e	03/18e	03/19e	
EPS	2.27	2.50	2.94	3.35	
% change	-	10.2%	17.6%	13.8%	
P/E	33.1x	30.0x	25.5x	22.4x	
FCF yield (%)	2.1%	2.5%	3.0%	3.5%	
Dividends (EUR)	1.60	1.60	1.60	1.60	
Div yield (%)	2.1%	2.1%	2.1%	2.1%	
EV/Sales	4.0x	3.9x	3.6x	3.3x	
EV/EBITDA	21.0x	18.4x	16.4x	14.4x	
EV/EBIT	23.5x	20.2x	18.1x	15.8x	

Return to front page

Sharp acceleration in sales trend

Fair Value EUR84 (+12%)

BUY-Top Picks

Q2 2016/17 sales increased 6.2% to EUR294.8m, 4% above expectations (consensus: EUR284m and our estimate: EUR283m). The group posted 7.4% organic sales growth (consensus: +4.3% and our estimate: +3.3%), implying a strong improvement vs Q1 (flat sales), driven by Cognac and Liqueurs & Spirits. These two divisions were impacted in the previous quarter by some destocking following a global hike in prices at the beginning of 2016/17

ANALYSIS

Q2 2016/17 sales increased 6.2% to EUR294.8m, 4% above expectations (consensus: EUR284m and our estimate: EUR283m). The group posted 7.4% organic sales growth (consensus: +4.3% and our estimate: +3.3%), implying a strong improvement vs Q1 (flat sales), driven by Cognac and Liqueurs & Spirits. These two divisions were impacted in the previous quarter by some destocking following a global hike in prices at the beginning of 2016/17. By division:

Cognac (62% of group's sales): Q2 organic sales grew 9.3% (consensus: +6% and our estimate: +5%), accelerating vs Q1 (-0.5%) thanks to a 1/ return to growth in Greater China (marketing initiatives on Louis XIII) and a 2/ strong performance in the United States fuelled by the intermediary product *1738 Accord Royal*.

Liqueurs & Spirits (26% of group's sales): Sales increased 10.1% organically in Q2 (consensus: +5% and our estimate: +3%) after -0.8% in Q1. The improved performance reflected a lack of negative technical effects that impacted the previous quarter (timing of Easter and destocking). The group reported good growth at Cointreau, Metaxa and the Islay Spirits, only partly offset by the decline at Mount Gay and St-Rémy as a result of the upscaling process.

Partner brands (12% of group's sales): On an organic basis, sales fell 10.7% (consensus: -8% and our estimate: -7%) over the quarter because of the loss of the distribution contract for the EPI champagne brands in France, Benelux and Travel Retail. But sales of other partner brands continued to enjoy a healthy momentum.

Outlook: The group confirmed its aim to achieve growth in EBIT at constant FX and scope. The conference call at 9am CET should provide some colour concerning consumption trends in China, in particular during the Mid-Autumn festival. In Q1 2016/17, value depletions were up mid single digit while they were flat in 2015/16.

VALUATION

We maintain our estimates before the conference call. Our DCF points to a Fair Value of EUR84. At yesterday's share price, the stock is trading at 20.2x EV/EBIT 2016/17e and 18.1x EV/EBIT 2017/18e, 14% and 13% above the average of the European spirits groups. This compares to a 10-year historical premium vs the peers of 18%.

NEXT CATALYSTS

Pernod Ricard is due to publish its Q1 2016/17 sales on 20th October

Click here to download





Analyst : Virginie Roumage 33(0) 1.56.68.75.22 vroumage@bryangarnier.com Sector Team : Nikolaas Faes Loïc Morvan Antoine Parison Cédric Rossi

Return to front page

Luxury & Consumer Goods Burberry Price 1,512p

Bloomberg			BRBY LN			
Reuters			BRBY.L			
12-month High / L	.ow (p)		1,530 / 1,041			
Market Cap (GBPr	n)		6,686			
Avg. 6m daily volu	ıme (000)			2 492		
	1 M	3 M	6 M 3	1/12/15		
Absolute perf.	16.2%	19.8%	18.8%	26.5%		
Pers & H/H Gds	-0.7%	-2.7%	0.0%	-0.8%		
DJ Stoxx 600	-0.1%	-0.1%	-1.6%	-7.8%		
	03 /15	03/16e	03/17e	03/18e		
P/E	19.7x	21.6x	21.0x	18.2x		
Div yield (%)	2.3%	2.4%	2.4%	2.4%		

Underlying sales down 4% in H1! Q2 retail sales rebound thanks to GBP weakness Fair Value 1200p (-21%) NEUTRAL

ANALYSIS

.

- H1 sales reached GBP1.16bn (consensus: GBP1.17bn), down 4% underlying (-3% expected by consensus). Retail sales were up 2% underlying during H1 (unchanged in Q1), implying some improvement in Q2. Retail comparable sales were almost unchanged (versus -0.5% expected by the consensus) in H1, implying +2% in Q2 alone after -3% in Q1. By region, note the low single digit comparable retail sales in APAC, in line with Q1. Although Mainland China was up mid-single digit in Q2, Hong Kong sales declined double digit in HY. The main driver of the Q2 retail sales rebound was EMEIA with a low single digit increase in H1 (low single digit decline in Q1), thanks to 30% comparable sales growth in the UK in Q2, fuelled by tourist flows. Momentum in the Americas (low single digit decline) was in line with Q1.
- However, wholesale sales were down 14% underlying (-12% expected by consensus). This decline, was slightly higher than expected and was driven by inventory control by wholesale retailers in the Americas, and in the US particularly.
- For FY 2016 guidance: wholesale sales should be down mid-teens, which is below anticipations, as it does not expect any improvement vs the H1 performance. On the other hand, the positive FX impact should be higher than initially expected with a GBP125m impact vs GBP90m previously.

VALUATION

The Burberry share price is almost stable YTD in EUR, almost in line with the sector average. We
remain Neutral on the stock.

NEXT CATALYSTS

H1 results to be released on 9th November.

Loïc Morvan, Imorvan@bryangarnier.com

Business Services

Bureau Veritas Price EUR18.39

Bloomberg Reuters 12-month High / Low (EUR) Market Cap (EUR)

Avg. 6m daily vo		636.7		
	1 M	3 M	6 M 3	1/12/15
Absolute perf.	-3.0%	-3.9%	-10.5%	0.0%
Inds Gds & Svs	-0.6%	3.5%	3.2%	1.9%
DJ Stoxx 600	-0.1%	-0.1%	-1.6%	-7.8%
	2015	2016e	2017e	2018e
P/E	19.2x	18.8x	18.0x	16.7x
Div yield (%)	2.8%	2.8%	2.9%	3.2%

Q3 revenue: Substantially lower and FY guidance downgraded

Fair Value EUR21 (+14%)

NEUTRAL

ANALYSIS

BVI FP

BVLPA

8,128

21.0 / 16.1

Q3 revenue largely misses consensus...: Bad surprise for Q3 revenue at EUR1,136m down 0.6% in reported terms with IfI revenue growth down 1% vs. +0.4% anticipated by consensus i.e. the rebound expected in Q3 after negative numbers in Q1 (-0.6%) and Q2 (-0.6) moved to a higher negative figure. Management gave two main explanations for this situation:

- Marine (8.7% consolidated revenue) revenue was down 9.8% Ifl in Q3 (after +1.2% in Q1 and 4.8% in Q2) hit earlier than expected by the shipping cycle downturn;
- Still challenging markets in Oil & Gas capex (c.8% of consolidated revenue depending on oil & gas client capex) down 21%.
- On the other hand, trends were better in **Consumer Products** (14.2% consolidated revenue), up 4.5% Ifl (1.6% in Q1 and 3.1% in Q2), **Certification** (7.6%) up 7.6% (+3.6% in Q1 and 6.9% in Q2) and recovered in **Commodities** (16.7%) with especially Metal & Minerals back to positive.

... forcing management to revise down its FY expectation: For 2016, management now expects a "slightly negative" figure for Ifl growth vs. between 1-3% previously and 0.4% forecast by the consensus (our forecast was based on 0.9%). In view of this, adjusted operating margin is lowered to between 16-16.5% vs. 16.5%-17% after 16.7% in 2015. The consensus is at 16.6% and our forecast was 16.3%.

VALUATION

At the current share price, and before adjustment the stock is trading on 2016e and 2017e EV/EBIT multiples of 13.2x and 12.4x respectively, compared with an historical median of 14.3x and CAGR 2015-2018 EBIT of 2.8%.

Based on consensus previous anticipations (Ifl growth of 0.4% with adjusted operating margin of 16.6%), new guidance would impact valuation of around 3.5%.

NEXT CATALYSTS

Conference call at 6.00pm

FY results on 24th February

Click here to download

Bruno de La Rochebrochard, bdelarochebrochard@bryangarnier.com

Return to front page

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

	Stock futing
BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock
	will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to
	be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary
	event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key
	reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a
	recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock
	will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 56.7%

NEUTRAL ratings 31.2%

SELL ratings 12.1%

Bryan Garnier Research Team

	J			
Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
ТМТ	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/Infrastructu	ures/Building Materials	Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Automotive & Parts		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information	on Systems Manager	Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London

Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)



Paris

26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudential et de resolution (ACPR)

New York 750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member

Munich

Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB, United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris, France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited in the or it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investors which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....